Omeros Corporation (NASDAQ:OMER) has announced that it will give a presentation at the 2016 Wedbush PacGrow Healthcare Conference which will take place in New York.
The event is slated to take place on August 17. Omeros Corporation’s chairman and chief executive officer Gregory A. Demopulos will be the person giving the presentation on behalf of the company. The presentation will be streamed live on the firm’s website and it will also be available afterward via the same website in the webcast archive. Details about the presentation are scanty because the firm has not revealed further information about the content that should be expected in the presentation.
Omeros’ main agenda as a biopharmaceutical company is to discover, develop and commercialize orphan indications that target disorders, coagulopathies, and inflammations that affect the central nervous system. It also deals with protein and small-molecule therapeutics that target large markets. The company’s PharmacoSurgery platform alongside OMIDRIA which is the firm’s first drug had a major debut in 2015 in the US. OMIDRIA is used in intraocular lens replacement or to prevent intraoperative miosis and maintain pupil size. The drug can also ease postoperative ocular pain. The drug was approved by the European Commission for use during cataract surgery.
Omeros is currently carrying out clinical development programs for various conditions. Some of the programs include preventing problems that arise during urologic surgical procedures. It is also working on a program that deals with cognitive impairment and Huntington’s disease. Omeros is also developing complement-related thrombotic microangiopathies. Analysts speculate that the presentation might involve a breakthrough in one of the company’s development.
Demopulos will most likely talk about the company’s efforts in product development seeing as the event is a healthcare conference. There is, therefore, a very minimal chance that the CEO will talk about matters relating to the performance of the company’s stock. Nonetheless, the information that the CEO will reveal is expected to arouse reactions from investors. Members of the healthcare committee are expected to be in attendance.